1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
BrainsWay Ltd.

BrainsWay Ltd.

BRSYF
BrainsWay Ltd.US flagOther OTC
16.84
USD
- -
- -
675.08MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.09
0.24
0.47
0.79
0.75
0.99
1.13
0.98
0.96
0.81
0.98
1.26
1.37
1.46
Basic EPS, GAAP
-0.55
-0.46
-0.28
-0.17
-0.48
-0.39
-0.5
-0.24
-0.21
-0.4
-0.13
0.09
0.2
0.23
Free Cash Flow per Basic Share
-0.5
-0.37
-0.47
-0.19
-0.3
-0.35
-0.51
-0.17
-0.04
-0.29
0.04
0.2
0.43
0.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-2.92
-3.15
-3.3
-3.72
-3.69
-3.5
-3.43
-2.71
-2.9
-3.13
-3.02
-2.37
-2.28
Tangible Book Value per Share
- -
1.1
0.89
0.71
0.86
0.42
1.18
0.88
1.86
1.36
1.29
1.92
1.92
1.96
Basic Weighted Avg Shares
13
14
14
15
15
17
21
22
31
33
32
32
38
39
Sales/Revenue/Turnover
1
3
7
12
11
16
23
22
30
27
32
41
52
56
Operating Margin (%)
-358.87
-215.3
-66.25
-17.95
-59.32
-31.19
-36.69
-21.89
-16.86
-46.67
-15.6
3.39
8.28
10.23
Depreciation Expense
- -
- -
1
1
1
1
2
2
2
2
1
2
2
2
Net Income, GAAP
-7
-7
-4
-2
-7
-6
-10
-5
-6
-13
-4
3
8
9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.55
1
0.45
Profit Margin (%)
-598.99
-193.64
-60.1
-20.8
-63.29
-39.51
-44.71
-24.41
-21.79
-49.12
-13.2
7.12
14.62
15.68
Working Capital
- -
14
10
9
12
5
22
17
56
50
46
64
63
55
LT Debt
- -
- -
- -
- -
3
2
- -
- -
- -
- -
- -
5
6
6
Total Equity
- -
16
13
10
13
7
24
20
57
45
42
62
73
76
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.16
5.82
7.54
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-4.36
-11.17
-12.64
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
39
40
Market Capitalization
213
334
459

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
83
85
79
Cash, Cash Equivalents & STI
72
69
60
Accounts Receivable, Net
5
4
8
Inventories
4
7
7
Total Current Liabilities
26
22
24
Payables & Accruals
9
9
11
ST Debt
1
1
1
Deferred Revenue
16
12
12

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.77%
46.02%
17.51%
Free Cash Flow
104.85%
199.81%
150.2%
Net Income, GAAP
20.61%
9.95%
161.31%
Sales/Revenue/Turnover
24.91%
19.89%
27.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
10
11
11
41
2025
12
13
14
15
52
2026
16
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
0.02
0.04
0.09
2025
0.03
0.05
0.04
0.08
0.2
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hadar Levy
Full Time Employees
120
Sector
Healthcare
Industry
Medical - Devices
Address
Bynet Building Jerusalem Israel 9777518
IPO Date
Apr 21, 2011
CIK
0001505065
Website
brainsway.com
Similar Companies
Coloplast A/S (CLPBY)
Vivos Inc. (RDGL)
Antibe Therapeutics Inc. (ATE.TO)
Eurobio Scientific S.A. (ALERS.PA)
Alphatec Holdings, Inc. (ATEC)
Forza Innovations Inc. (FORZ)
Business
BrainsWay Ltd. (NASDAQ: BWAY; TASE: BWAY) develops and commercializes noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology that stimulates deeper and broader brain regions than standard TMS devices; core offerings include FDA-cleared Deep TMS systems with H1-coil for major depressive disorder and comorbid anxious depression (including late-life depression in patients aged 68-86 and now ages 15-86), H7-coil for obsessive-compulsive disorder, and H4-coil for short-term smoking cessation, marketed through system sales, leases, disposable coils, and session-based fees to psychiatrists, clinics, hospitals, and addiction centers. The Israel-based company, founded in 2003 and headquartered at 19 Ha'barzel Street in Jerusalem, operates globally in the United States, East Asia, Europe, and other international markets, with over 950 systems installed worldwide and a workforce exceeding 180 employees focused on R&D for additional indications such as post-traumatic stress disorder, bipolar disorder, schizophrenia, chronic pain, and Alzheimer's disease. Recent developments include a US$20 million private placement with Valor Equity Partners in September 2024 to bolster its balance sheet and strategic growth; a $5 million convertible loan investment in Neurolief Ltd. in 2025 to enter at-home neuromodulation for depression via wearable technology, with options for up to $11 million more and potential full acquisition; additional 2025 investments in Axis Integrated Mental Health ($3.3 million) and Stella Mental Health; and new FDA clearances expanding Deep TMS to adolescent MDD patients (ages 15+) and late-life depression, alongside Q3 2025 revenue growth of 29% to $13.5 million with positive operating income and adjusted EBITDA.

Company News

APIChat

  • seekingalpha.com

    BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript